Stock Market and Genentech Essay

Submitted By Ankita-Sanghvi
Words: 1683
Pages: 7
Open Document
Case Study
1. Why is Roche seeking to acquire the 44% of Genentech it does not own? From Roche’s point of view, what are the advantages of owning 100% of Genentech? What are the risks?
Roche already had 56% of shares of Genentech and now it seeks to acquire rest of the 44% shares so as to get the benefits of synergies. The pharmaceutical companies have been unable to introduce new products lately, and their only way to remain profitable is by mergers and acquisitions. Roche also used this method. Acquisition will help the firm compete in the market and thus will help it grow.

Advantages of owning 100% of Genentech’s shares:
The merger will lead to formation of the world’s largest biotechnology company.
Value of total benefit from synergies will be $5billion. This will be a result of M&D, manufacturing, development and administrative costs reduction.
Complete ownership will give the company complete access to technology and R&D projects.
It will also give the company access to its cash amounting to $9.5billion, which can also be used to make payment for debt raised for acquisition.
The company can also create a contract allowing it to distribute Genentech’s best selling drugs.
Risks of owning 100% of Genentech’s shares:
The acquired company’s minority shareholders are mostly its employees. The company’s culture is like a family environment where all the employees work in cohesion. Acquisition may destroy this culture. The culture of Genentech will have to be matched and combined with the culture of Roche. This may create problems for the human resources which may even lead to high employee turnover.
There is a chance that the company pays higher than the premium required for the benefits of synergies. Such a situation may lead to drop in the prices of Roche’s shares.
For the deal, Roche has to borrow around $30 billion. The ongoing financial crisis could make the debt financing even more difficult to obtain as well as more expensive.
The contract gives Roche the right to sell Genentech on non US markets, but only till 2015. After that the company faces a high risk of losing the right.
Genentech’s cancer drug, Avastin, may not be successfully tested and may be banned from sale. This risk of loss of revenue will also have to be borne by the company.
New competitors may come with competing best selling drugs, which will again lead to a risk of reduction in growth prospects.

2. As a majority shareholder of Genentech, what responsibilities does Roche have to the minority shareholders?

The affiliation agreement signed in 1999 stated the obligations to minority shareholders, which are as follows:
Board approval is sufficient in case of a friendly bid. Roche can buy all shares for same price
When the takeover is hostile, in which Roche would get at least 90% of shares and would hold them for at least 2 months, it will squeeze out the existing shareholders and will merge the company. It is an optional measure and not a necessary one, as per Delaware law.
As explained earlier, minority shareholders are majorly the employees of the company. It is Roche’s duty to explain the benefits of merger to them and retain them.

3. As of June 2008, what is the value of the synergies Roche anticipates from a merger with Genentech? Assess the value of synergies per share of Genentech. Please use a 9% weighted average cost of capital in your analysis. Synergies are given in an exhibit.

Value of synergies:

WACC
9%

2009
2010
2011
2012
2013 and thereafter
FCF
$138.05
$362.36
$436.47
$475.58
$488.81
Terminal Value
$5,431.22

Discounted
$3,529.92

Shares
1052
NPV
$1,423.28

Shares to buy
463
Total value
$4,953.21

Value per share
$10.70

2013 cash flows are treated as a perpetuity (ignoring 2% long term growth rate).

4. Based on DCF valuation techniques, what range of values is reasonable for Genentech as a stand-alone company in June 2008? Please exclude synergies from your valuation and
Show More

Related Documents: Stock Market and Genentech Essay

A Brief Note On 21st Century Leadership

He was able to restore the company’s reputation from these allegations and initial failures. In March of 2003 the drug Avastin failed final stages of testing for treatment of breast cancer and lead to a huge loss on the stock market and investors demanding answers. He was able to take the data from the final testing and his company was able to find that the drug Avastin significantly extended the life of patients with colon cancer.(Levine, 2004) It was filed for approval…

Words 1994 - Pages 8

Strategic Management Essay

and figures related to the current financial condition in the share market would give us a better perspective and answers of all this mysteries surrounding apple’s financial crisis. Strategic Management in Dynamic Environments Individual Project 1 2 Foundation NASDAQ (2013) On January 3, 1977 Apple.inc formerly apple computers incorporated a variety of products. Revolutionizing the manufactures and markets mobile communication by its unique designs, and media devices, portable…

Words 3503 - Pages 15

Amgen Essay

mindset of helping his subordinates succeed in order to succeed himself. Clearly this philosophy proved to be beneficial as the company prospered and became well known for being a great employer. As of the year 2000 Binder lead the company to be the stock market’s fourteenth largest pharmaceutical company of the world. This philosophy was carried on by CEO’s through the years bringing the company more and more success (Quiet). Now in 2012 Forbes magazine ranks Amgen two-hundred and twelve on their…

Words 930 - Pages 4

Revenue and Biogen Essay examples

Biogen Idec Inc. was formerly known as IDEC Pharmaceuticals Corporation before changing its name in November 2003. Biogen finds itself in the Biotechnology industry, which is the second largest industry in the Healthcare sector, a sector that has a market capitalization of over 60 trillion dollars and an average ROE of 18.42%. The Biotechnology industry shares its participation with many other important industries in this sector such as: drug manufacturers, medical appliances & equipment, health…

Words 5823 - Pages 24

Biodel Inc Essays

Biodel created a synthetic serum to replace fetal calf serum and horse serum, and provide a more consistently available product for scientific researchers. Biodel’s Molecular Biology division used DNA technology to gain 60% of the market share of growth factors and stock the largest collection of commercially available synthetic nucleotides, which was 50% of their sales. Biodel’s research and development in Immunodiagnostics led to the invention of DEMA, a…

Words 1904 - Pages 8

Madalyn Chaffin Strategic Plan For Apple Inc.

to regain trust in Apple from the investors driving the value of Apple’s stock. (45 percent within four weeks) 3. To have an effect of acceptance, by investors supporting Apple’s decisions. (35 percent within four weeks) 4. To have an effect of action, specifically by maintaining all current investors. (100 percent within four weeks) 5. To have an effect of action, particularly to increase share prices by purchasing more stock in Apple. (15 percent within 6 weeks) Communication Strategies Our proactive…

Words 3338 - Pages 14

Fundamental Analysis and Aswath Damodaran Essay

Needed: To use discounted cash flow valuation, you need • • •  to estimate the life of the asset to estimate the cash flows during the life of the asset to estimate the discount rate to apply to these cash flows to get present value Market Inefficiency: Markets are assumed to make mistakes in pricing assets across time, and are assumed to correct themselves over time, as new information comes out about assets. Aswath Damodaran 5 DCF Choices: Equity Valuation versus Firm Valuation Firm Valuation:…

Words 9402 - Pages 38

Essay about apple computer 2002

technology. Apple was still maintaining the leader position until the mid 1980’s when IBM entered the PC market, Dell, Compaq and HP were soon to follow, and they have taken some market share from Apple. In this bad situation, Apple…

Words 6688 - Pages 27